206 related articles for article (PubMed ID: 19197554)
1. Septic shock after treatment of pyoderma gangrenosum with infliximab.
Wölbing F; Fierlbeck G; Hötzenecker W; Schaller M; Röcken M
Acta Derm Venereol; 2009; 89(1):93-4. PubMed ID: 19197554
[No Abstract] [Full Text] [Related]
2. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
Tanczos BT; Baumgart DC
Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
[No Abstract] [Full Text] [Related]
3. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
4. Six patients with pyoderma gangrenosum successfully treated with infliximab.
Mooij JE; van Rappard DC; Mekkes JR
Int J Dermatol; 2013 Nov; 52(11):1418-20. PubMed ID: 22512250
[No Abstract] [Full Text] [Related]
5. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
6. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Stichweh DS; Punaro M; Pascual V
Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
8. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
Adişen E; Oztaş M; Gürer MA
Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests.
Uthman I; El-Sayad J; Sharara A
Clin Exp Dermatol; 2005 May; 30(3):294. PubMed ID: 15807693
[No Abstract] [Full Text] [Related]
10. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin.
Sinagra E; Orlando A; Renna S; Maida M; Cottone M
Inflamm Bowel Dis; 2012 Aug; 18(8):E1594-5. PubMed ID: 22038892
[No Abstract] [Full Text] [Related]
11. [Infliximab treatment of peristomal pyoderma gangrenosum in ulcerative colitis].
Nybaek H; Jemec GB
Ugeskr Laeger; 2005 Aug; 167(32):2920-1. PubMed ID: 16109221
[No Abstract] [Full Text] [Related]
12. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
[TBL] [Abstract][Full Text] [Related]
13. Severe recalcitrant pyoderma gangrenosum treated with infliximab.
Kaur MR; Lewis HM
Br J Dermatol; 2005 Sep; 153(3):689-91. PubMed ID: 16120178
[No Abstract] [Full Text] [Related]
14. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
Brooklyn TN; Dunnill MG; Shetty A; Bowden JJ; Williams JD; Griffiths CE; Forbes A; Greenwood R; Probert CS
Gut; 2006 Apr; 55(4):505-9. PubMed ID: 16188920
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
16. Miliary tuberculosis after infliximab therapy in Lebanon.
Uthman I; Kanj N; El-Sayad J; Bizri AR
Clin Rheumatol; 2004 Jun; 23(3):279-80. PubMed ID: 15168166
[No Abstract] [Full Text] [Related]
17. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.
Shareef MS; Munro LR; Owen RG; Highet AS
Clin Exp Dermatol; 2012 Mar; 37(2):146-8. PubMed ID: 22103549
[TBL] [Abstract][Full Text] [Related]
18. Refractory pyoderma gangrenosum treated with infliximab in an infant.
Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic manifestations of Crohn disease in children: response to infliximab.
Kugathasan S; Miranda A; Nocton J; Drolet BA; Raasch C; Binion DG
J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):150-4. PubMed ID: 12883301
[TBL] [Abstract][Full Text] [Related]
20. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Hubbard VG; Friedmann AC; Goldsmith P
Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
